Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
The effects induced by oral administration of 0, 5 and 20 mg of meparticin kg(-1)of body weight for 28 days (group 1, 2 and 3, respectively) upon prostatic estrogen, androgen, alpha(1)- and beta-adrenergic receptor concentrations and on estradiol and testosterone serum levels in adult male rats were studied. The effects produced by mepartricin treatments on the weight and dimension of the gland were investigated. Both mepartricin dosages induced significant decreases (P< 0.05) of the absolute and relative weights and of the dimensions of the prostate. A significant dose-dependent decrease (P< 0.05) in estradiol serum levels was observed in treated rats, whereas no significant modifications were found in testosterone serum levels. As far as prostatic steroid receptor concentrations were concerned, a significant (P< 0.05) decrease in estrogen receptor number was observed in both treated groups, whilst a significant increase (P< 0.05) of androgen receptor concentrations was recorded only in rats treated with 20 mg mepartricin kg(-1). Conversely, a dose-dependent up-regulation of both prostatic alpha(1)- and beta-AR was found. Data obtained suggest that the prostatic alpha(1)-AR expression may be strongly influenced by estrogen deprivation (mepartricin treatment), therefore the combination of estrogen suppression (mepartricin) and adrenergic suppression (alpha(1)-AR blockers) may be suggested as a possible pharmacotherapeutic strategy for the treatment of benign prostatic hyperplasia.
Re
G
G
Department of Animal Pathology, Division of Pharmacology & Toxicology, University of Torino, via Leonardo da Vinci 44, I-10095 Grugliasco (TO), Italia. re@veter.unito.it
Badino
P
P
Odore
R
R
Vigo
D
D
Bonabello
A
A
Rabino
S
S
Capello
F
F
Bruzzese
T
T
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood*; D008297:Male; D008613:Mepartricin / Q000009:adverse effects / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000097:blood / Q000139:chemically induced / Q000000981:diagnostic imaging; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D013739:Testosterone / Q000097:blood*; D014463:Ultrasonography
D000900:Anti-Bacterial Agents; D011941:Receptors, Adrenergic; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D008613:Mepartricin; D013739:Testosterone; D004958:Estradiol